Greater Glasgow and Clyde Medicines

Click here to access the full blog

• A new regional West of Scotland Formulary is in development and will replace the NHSGGC formulary over time.
• The July 2026 edition of the regular Formulary Focus newsletter has been issued to keep staff in participating Health Boards up-to-date with progress.
• Six chapters are now available in the new formulary, with the Endocrine and Infections chapters being the latest to launch, on 30th July 2026.

Click here to access the full blog

Click here to access the full blog

New published chapters: endocrine and infections

Click here to access the full blog

• Emollients are typically under-prescribed and under-used. This results in suboptimal treatment of dermatological conditions, and may increase the occurrence of flares.
• Patients should be advised to use emollients liberally and frequently, even when their skin appears to return to normal. For guidance on appropriate quantities to supply on prescription see blog.

Click here to access the full blog

• Generic dapagliflozin is the most cost-effective SGLT2 inhibitor for all licensed indications.
• Where clinically appropriate, clinicians may wish to consider generic dapagliflozin as the preferred cost-effective option when prescribing an SGLT2 inhibitor.
• Clinical choice remains guided by existing CKD, diabetes and heart failure guidelines.
• Patients on SGLT2 inhibitors will be switched to generic dapagliflozin, where clinically appropriate, ensuring patient safety and continuity of care are prioritised throughout the process.

Click here to access the full blog

• From 22nd July 2026 NHSGGC are switching to enoxaparin for treatment LMWH doses in adults due to rising costs of dalteparin. This change has been endorsed by the Acute Services Prescribing Management Group (ASPMG). 

• The GGC Adult Therapeutics Handbook and GGC clinical guidelines are being updated to reflect this. 

• Treatment enoxaparin subcutaneous (SC) dosing is based on thrombosis risk, patient weight and renal impairment – a dose banding table will be available in the Adult Therapeutics Handbook to support this. 

• Take extra care with prescribing in renal impairment and low body weight as these patients may be on a 40mg SC once daily treatment dose of enoxaparin, i.e. a dose commonly used for prophylaxis of venous thromboembolism (VTE). 

Click here to access the full blog

• A new NHSGGC clinical guideline: Cranial Diabetes Insipidus, Inpatient Management is now available on NHSGGC Right Decisions for Health and Care Platform.
• This guideline is aimed at managing adult patients with known cranial diabetes insipidus (DI) who are admitted to general wards. It excludes patients with AVP resistance (Nephrogenic DI); a new diagnosis of cranial DI; patients post pituitary surgery; pregnant or ICU patients.
• All patients with cranial DI should be identified and referred to Endocrine team on admission to hospital and have U&Es monitored frequently.
• Desmopressin must be administered on time and as prescribed and doses MUST NOT be omitted without senior clinical advice. Omission or delay in desmopressin treatment could result in patient harm. 
• In patients with compromised oral route, equivalent doses can be administered via an alternative route and guidance on equivalent doses is provided.
• The guideline also outlines the management of sodium disorders in patients with known cranial DI on desmopressin. 

Click here to access the full blog